Lacosamide Pharmacokinetics in a Critically Ill Patient Receiving Continuous Venovenous Hemofiltration

2017 ◽  
Vol 38 (2) ◽  
pp. e17-e21 ◽  
Author(s):  
Miguel J. Franquiz ◽  
Shamir N. Kalaria ◽  
Michael J. Armahizer ◽  
Mathangi Gopalakrishnan ◽  
Paul J. McCarthy ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patient ◽  
Continuous Venovenous Hemofiltration

scholarly journals Evaluation of Sulfobutylether-β-Cyclodextrin Exposure in a Critically Ill Patient Receiving Intravenous Posaconazole While Undergoing Continuous Venovenous Hemofiltration

2015 ◽  
Vol 59 (10) ◽  
pp. 6653-6656 ◽  
Author(s):  
Amanda A. Morris ◽  
Scott W. Mueller ◽  
Joseph E. Rower ◽  
Taylor Washburn ◽  
Tyree H. Kiser
Keyword(s):  
Bone Marrow ◽  
Steady State ◽  
Bone Marrow Transplantation ◽  
Critically Ill ◽  
Allogeneic Bone Marrow Transplantation ◽  
Significant Risk ◽  
Critically Ill Patient ◽  
Allogeneic Bone ◽  
Continuous Venovenous Hemofiltration ◽  
Pulmonary Mycosis

ABSTRACTWe present a 31-year-old female who had undergone an allogeneic bone marrow transplantation and who was started on intravenous posaconazole for pulmonary mycosis while undergoing continuous venovenous hemofiltration (CVVH). We performed steady-state pharmacokinetic evaluations for both posaconazole and sulfobutylether-β-cyclodextrin (SBECD). SBECD was effectively removed by CVVH, with observed exposure similar to that for patients with moderate renal impairment. Intravenous posaconazole at standard doses may be utilized in critically ill patients undergoing CVVH without significant risk of SBECD accumulation.

Extracorporeal Clearance of Levetiracetam During Continuous Venovenous Hemofiltration in a Critically Ill Patient and New Dosing Recommendation

2016 ◽  
Vol 57 (4) ◽  
pp. 536-537 ◽  
Author(s):  
Jos L.M.L. le Noble ◽  
Norbert A. Foudraine ◽  
Francois H.M. Kornips ◽  
Davy G.H.A. van Dam ◽  
Cees Neef ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patient ◽  
Continuous Venovenous Hemofiltration

scholarly journals Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration

2015 ◽  
Vol 60 (3) ◽  
pp. 1899-1901 ◽  
Author(s):  
Wesley D. Oliver ◽  
Emily L. Heil ◽  
Jeffrey P. Gonzales ◽  
Shailly Mehrotra ◽  
Kathryn Robinett ◽  
...  
Keyword(s):  
Critically Ill ◽  
Multidrug Resistant ◽  
Critically Ill Patient ◽  
Continuous Venovenous Hemofiltration ◽  
Time Curve ◽  
Content Type ◽  
Dosing Interval ◽  
Drug Concentrations ◽  
Extended Infusion ◽  
Susceptibility Breakpoint

Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistantPseudomonas aeruginosain a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 μg/ml, time toCmax(Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0–8) of 284.38 μg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.

scholarly journals Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration

2017 ◽  
Vol 61 (7) ◽  
Author(s):  
Eric Wenzler ◽  
Kristen L. Bunnell ◽  
Susan C. Bleasdale ◽  
Scott Benken ◽  
Larry H. Danziger ◽  
...  
Keyword(s):  
Steady State ◽  
Plasma Concentration ◽  
Critically Ill ◽  
Critically Ill Patient ◽  
Pharmacokinetic Parameters ◽  
Maximum Plasma ◽  
Continuous Venovenous Hemofiltration ◽  
Total Clearance ◽  
Time Curve ◽  
Drug Concentrations

ABSTRACT Ceftazidime-avibactam administered at 1.25 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa bacteremia in a critically ill patient on continuous venovenous hemofiltration (CVVH). Prefiltration plasma drug concentrations of ceftazidime and avibactam were measured at 0, 1, 2, 4, 6, and 8 h along with postfiltration and ultrafiltrate concentrations at h 2 and h 6. Plasma pharmacokinetic parameters of ceftazidime and avibactam, respectively, were as follows: maximum plasma concentration (C max), 61.10 and 14.54 mg/liter; minimum plasma concentration (C min), 31.96 and 8.45 mg/liter; half-life (t 1/2), 6.07 and 6.78 h; apparent volume of distribution at the steady state (V ss), 27.23 and 30.81 liters; total clearance at the steady state (CLss), 2.87 and 2.95 liters/h; area under the concentration-time curve from 0 to 8 h (AUC0–8), 347.87 and 85.69 mg · h/liter. Concentrations of ceftazidime in plasma exceeded the ceftazidime-avibactam MIC (6 mg/liter) throughout the 8-h dosing interval. Mean CVVH extraction ratios for ceftazidime and avibactam were 14.44% and 11.53%, respectively, and mean sieving coefficients were 0.96 and 0.93, respectively. The calculated mean clearance of ceftazidime by CVVH was 1.64 liters/h and for avibactam was 1.59 liters/h, representing 57.1% of the total clearance of ceftazidime and 54.3% of the total clearance of avibactam. Further data that include multiple patients and dialysis modes are needed to verify the optimal ceftazidime-avibactam dosing strategy during critical illness and CVVH.

The timing of tracheostomy in critically ill patient

ORL ro ◽  
2017 ◽  
Vol 2 (35) ◽  
pp. 20
Author(s):  
Liliana Mirea ◽  
Raluca Ungureanu ◽  
Daniel Mirea ◽  
Mirela Țigliș ◽  
Ioana Cristina Grințescu ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patient
Sign in / Sign up

Export Citation Format

Share Document